The United States Food and Drug Administration (FDA) has issued its weekly regulatory update for stakeholders. You can read the FDA regulatory update for stakeholders below.
June 14, 2024
Dear Colleague,
While the FDA continues to focus on protecting the public’s health, using science to guide our decisions, and facilitating access to critical medical products, we also recognize the work of our public health partners. As public health advocates, we know that your work to better our country is invaluable. Your partnership, knowledge and engagement in the public health space are appreciated.
Advisory Committees Give FDA Critical Advice and the Public a Voice
At the U.S. Food and Drug Administration, we rely on our many advisory committees to help us make sound decisions based on the best science available.
The FDA’s complex and multifaceted mission includes evaluating new medical devices and medicines, including vaccines and other therapies, to determine if they are safe and effective for their intended use.
This edition of the Conversations on Cancer public panel discussion series will start with a brief exploration of the difference between religion and spirituality.
The FDA is announcing the following public workshop entitled " Evaluating Immunosuppressive Effects of In Utero Exposure to Drug and Biologic Products."
The Stakeholder Engagement Staff resides within the Office of the Commissioner and falls under the Office of External Affairs. We aim to build stronger relationships with health professional organizations, consumer groups, trade associations, patient advocacy organizations, think tanks/academia, and other stakeholders, in order to better inform our policy making process, identify policy hurdles or stakeholder misconceptions, and create strategic collaborations. For more information, please contact us at: FDAStakeholderEngagement@fda.hhs.gov.